中文The pharmaceuticals that dominate headlines today — blockbuster, novel and often fiendishly complex — are reshaping how the industry packages them. According to a MarketsandMarkets report, the global pharmaceutical fill-finish manufacturing market is predicted to grow from $19.75 billion in 2026 to $30.37 billion by 2031, a roughly 9% compound annual growth rate driven in large part by GLP-1/incretin injectables and other sophisticated therapies.
Contract manufacturing organisations are leading the charge. CMOs accounted for more than 61% of the global market in 2025 and are expected to be the fastest-growing end-user segment over the next five years. To meet demand, facilities are investing in sterile manufacturing upgrades — isolators, restricted access barrier systems (RABS) and other technologies built to satisfy standards such as EU GMP Annex 1.
Consumables are outpacing instruments. Vials, syringes, cartridges, stoppers and related components “are essential for maintaining sterility, ensuring product integrity, and supporting injectable fill-finish operations,” the research firm notes. Demand for ready-to-use (RTU) primary packaging is a particularly fast-growing slice.
Several companies are putting money behind that thesis. CDMO Curia expanded its Glasgow, UK, sterile drug facility and enhanced its cell-line development platform, adding an Annex 1-compliant isolator-based vial filling line and lyophilizer; in August it expanded sterile capacity in Albuquerque, New Mexico, with a new high-speed vial line. Drug-containment specialist Schott Pharma installed new lines for standard and sterile RTU glass vials at its Lebanon, Pennsylvania, site in June, investing in vials, cartridges and prefillable syringes for biologics, GLP-1 therapies and ADCs. “As therapies become more sensitive and administration models become more patient-centric, packaging must do more than contain a drug,” said Chris Cassidy, president of Schott Pharma USA.
Vetter, meanwhile, broke ground on a site in Saarlouis, Germany, and enhanced facilities in Ravensburg and Des Plaines, Illinois. Körber Pharma’s Michael McGown points to advances in robotics, gloveless isolators, AI for automatic visual inspection and single-use systems that cut contamination risk. “The industry, in general, is moving towards an isolator-based technology,” said Ranald Baillie of Curia’s Glasgow site, noting that “every filled unit meets specification” via robotic filling with 100% weight check.
The economics favour outsourcing. “You either build it, or you outsource it,” Baillie said of clinical-phase drugs, where building a sterile site for a product that may never reach market is expensive and risky. Smaller biotech firms in particular lean on CDMOs for aseptic expertise and scalable capacity. McGown acknowledges the trade-off: some loss of control versus “much more predictable costs” and worldwide partnership.
Scaling from clinical to commercial demands flexible systems. Körber advocates modular or dual-line equipment that transitions from micro-batch clinical vials to high-speed commercial lines, saving time and validation effort. Cassidy stresses choosing containment compatible with the intended process from day one, with RTU platforms easing changeovers.
Cold chain is another pressure point, growing at double-digit CAGR as temperature-sensitive biologics, cell therapies and mRNA formulations require unbroken cooling. “When a temperature excursion can put an entire batch at risk, that visibility becomes essential,” said Sade Mokuolu of Watson Marlow. Polymer formats such as COC and COP are trending for potent and cryo products.
The throughline is connectivity: manufacturers want equipment that integrates with digital systems, capturing process data and supporting consistent quality across sites. As Mokuolu put it, the more continuity maintained from clinical development to commercialization, the better. For an industry where a single contaminated vial can be catastrophic, that connected, controlled, data-driven discipline is now the price of entry — and the reason fill-finish has become one of the most capital-intensive, quality-obsessed corners of the entire packaging world. The GLP-1 phenomenon alone has reordered capacity planning across the supply chain, with drugmakers and their CDMO partners racing to add aseptic lines fast enough to meet demand that shows no sign of abating.
Source: Packaging Digest (Lisette Hilton), 2 September 2026.
The GLP-1 phenomenon alone has reordered capacity planning across the supply chain. Drugs such as semaglutide and tirzepatide are administered by injection, in chronic-therapy volumes, to tens of millions of patients — a step-change in sterile, ready-to-use packaging demand that drugmakers and their CDMO partners are still racing to satisfy. That single therapeutic class helps explain why CMOs already command a 61% share and why capacity is being added on both sides of the Atlantic simultaneously.
For conventional packaging suppliers, the signal is unmistakable: the highest-value growth in packaging is increasingly adjacent to pharma, where regulatory rigour, barrier performance and contamination control command premium pricing. Convertors comfortable with food and industrial flexible packaging are watching the aseptic and RTU segment closely, even as the qualification burden remains formidable. The winners will be those who can meet EU GMP Annex 1 expectations, integrate with customers’ digital systems and absorb the validation costs of scaling from clinical to commercial. As Mokuolu of Watson Marlow stresses, continuity of process from early development to commercial production is the cheapest path to market — and the fill-finish gold rush is really a race to build that continuity before competitors lock in the marquee pharma accounts.
